Study of puzo-cel for B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study looks at patients with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It aims to see how well a special cell therapy, called puzo-cel, works in real-life settings in China.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with B-cell acute lymphoblastic leukemia that has relapsed (come back) or is refractory (did not respond to previous treatment).
- You are scheduled to receive treatment with a medicine called pucicelant injection at a certified center in China.
- Your leukemia cells must show a marker called CD19 when tested in the lab.
- Your vital organs, like your heart, lungs, kidneys, and liver, must be working normally.
- You must be willing to join the study and sign a consent form (if under 18, your legal guardian must also sign).
- You must not test positive for hepatitis C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
This trial tests an investigational cell therapy called Azer-cel for people with certain types of blood cancer (non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia) that has come back or not responded to previous treatments. The therapy uses your own immune cells that have been modified to find and attack cancer cells.
This trial tests an experimental cell therapy using your own immune cells (gamma-delta T cells) that are engineered to find and kill cancer cells that carry a protein called CD19. It is for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
This trial tests a combination of a targeted drug and low-dose chemotherapy for adults newly diagnosed with a certain type of acute lymphoblastic leukemia (ALL). The goal is to find a gentler but effective treatment that may be easier for patients to tolerate.
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.